Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Get Alerts TCDA Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida,�Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 40th Annual Health Care Conference on Wednesday, June 12, 2019 at 10:00 am PT. Gerrit Klaerner, Tricidaâs Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the companyâs key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of an NDA to the U.S. Food and Drug Administration (FDA). Tricida plans to submit an NDA in the second half of 2019, seeking approval of veverimer through the FDAâs Accelerated Approval Program.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including for example, statements about our ability to submit an NDA for veverimer under the FDAâs Accelerated Approval Program. Forwardâlooking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forwardâlooking statements. These risks and uncertainties include, among others, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis or at all; there can be no assurance that the FDA would approve an NDA under the Accelerated Approval Program, or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; possible safety and efficacy concerns; and that we completely rely on third-party suppliers to manufacture our clinical drug supply. The forward-looking statements contained in this press release reflect Tricidaâs current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005256/en/
Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor
Relations and Communications
[email protected]
Source: Tricida, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mativ Announces Conference Call to Discuss First Quarter 2024 Results
- Zeebu Announces 'Zeebu by the Beach' Event During TOKEN2049 in Dubai
- Skyhigh Security Named a Visionary in the 2024 Gartner® Magic Quadrant™ for Security Service Edge
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Goldman Sachs, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!